Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Clinical trial NCT02523313 · COMPLETED

Trial details

NCT number: NCT02523313
Sponsor: Prof. Dr. med. Dirk Schadendorf
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2015-09-02
Primary completion: 2021-06-27
Enrollment: 167

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.